Mayo Clinic

Oxford BioMedica, Mayo Clinic collaborate in glaucoma research

Monday, October 31, 2011 11:04 AM

Oxford BioMedica has entered into a research and development collaboration with Mayo Clinic to develop a novel gene therapy for the treatment of chronic glaucoma. Under the terms of the agreement, Mayo Clinic and Oxford BioMedica will undertake pre-clinical studies to establish the feasibility of treating glaucoma using Oxford BioMedica's proprietary LentiVector gene delivery technology expressing a COX-2 gene and a PGF-2alpha receptor gene in order to reduce intraocular pressure. The collaboration includes an option for exclusive US rights to license Mayo Clinic's glaucoma technology, which Oxford BioMedica can exercise upon completion of pre-clinical studies under confidential terms agreed by Mayo Clinic and Oxford BioMedica.

More... »

Cardio3 establishes US subsidiary

Friday, September 23, 2011 10:35 AM

Belgian cardiac cell therapies firm Cardio3 BioSciences established a U.S. subsidiary in Rochester, MN, to support its clinical and development activities and to bolster existing links with the Mayo Clinic and other U.S. collaborators, according to GEN News. Cardio3’s lead product, C3BS-CQR-1 is a stem cell-based cardiac lineage in clinical development for the treatment of heart failure. Phase III studies are projected to start in 2012.

More... »

Mayo Clinic sees potential of social media in patient recruitment

Thursday, September 1, 2011 12:32 PM

Social media and online networks could be of particular value in initiating, and recruiting patients for, studies of sometimes neglected rare medical conditions, US-based non-profit Mayo Clinic has found, according to PharmaTimes.

More... »

Generex publishes trial results

Monday, July 11, 2011 12:28 PM

Generex Biotechnology has published studies conducted at the Mayo Clinic using the Antigen Express proprietary Ii-Key technology.  Antigen Express, Generex’s subsidiary, has used this technology platform in the development of self-potentiating immunotherapeutic vaccines for cancer. 

More... »

Extra tests do not deter cancer patients

Monday, March 7, 2011 01:50 PM

Cancer patients are willing to tolerate multiple injections, X-rays, ultrasounds, PET and CT scans to receive advanced experimental treatments in early-stage clinical trials, with some even amenable to extra tumor biopsies, according to HealthDay.

More... »

Mayo Clinic Closes Clinical Trial Services Unit

Monday, November 17, 2008 09:00 AM

Faced with an increasingly competitive market and possible financial losses in the future, Mayo Clinic is shutting down its 17-year-old Mayo Clinical Trial Services (MCTS) Unit.

More... »